65,437 trials
Hypertension
Primary: Awake Systolic Home Blood Pressure Measurement — 131.5 mmHg
Cocaine Dependence
Primary: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment. — 7; 5 participants
Encephalitis
Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…
Bulimia Nervosa · Body Dysmorphic Disorder
Primary: Number of Binge Eating and Self-induced Vomiting Episodes — 20.67; 31.33; 21.67; 36.67 number of episodes
Perennial Allergic Rhinitis
Primary: Percentage of Subjects Experiencing Adverse Events (AEs) — 51.5 percentage of participants
Perennial Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo — -3.45; -3.37; -2.48 units on a scale
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Number of Participants With Objective Radiographic Response (ORR) — 0 participants
Contact Lens Wear
Primary: Ex Vivo Contact Angle — 104.8; 104.9; 103.3 degrees
Corneal Staining
Primary: Corneal Staining by Wear Time — 19; 15; 19; 7 participants
Breast Cancer
Primary: Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo — 18.1; 16.1 weeks — p=0.148
Hot Flashes
Primary: Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day — -5.32; -6.19; -4.76; -8.44 Vasomotor symptoms per day — p=<0.0001
Multiple Myeloma
Primary: Overall Best Confirmed Response — 101; 6 number of participants
Colonic Diseases · Bowel Diseases
Primary: Accuracy of Detection in Patients With Colonic Polyps - Sensitivity — 89; 100 percentage of sensiivity
Asthma
Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period. — -1.74; -1.75; -0.72 Units on a scale — p=<0.0001